Johnson Matthey (www.jmfinechemicals.com), a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies and Domainex Ltd. (Cambridge, U.K.; www.domainex.co.uk), a small-molecule drug discovery company, have announced a collaboration to provide integrated small molecule pharmaceutical discovery and development services. The focus will be on providing academic institutes, biotechnology and pharmaceutical companies across the U.K. and beyond with effective, simplified, rapid and reduced risk target-to-lead identification, optimization, safety/toxicology, pre-clinical and clinical API supply services.
Domainex is a leading provider of small molecule drug discovery services that complement the pre-clinical to commercial range of services provided by Johnson Matthey Fine Chemicals’ Custom Pharma Solutions offering in Europe. Through an integrated offering co-located in the Cambridge region, customers will be able to access Domainex’s target-to-lead identification and optimization capabilities, and will then be able to transfer their projects directly to Johnson Matthey, utilizing its Pharmorphix solid state services for effective salt form and polymorph identification through to process development, scale-up and non-GMP toxicology manufacture. With all activities co-located in the Cambridge area, discovery and development time and risk can be greatly minimized.